What is Stereotaxis?
Stereotaxis is a leader in the development of innovative robotic systems designed for minimally invasive endovascular procedures. The company's technology provides physicians with unprecedented control and precision, facilitating complex interventions while improving patient outcomes. By integrating advanced robotics with real-time data, Stereotaxis addresses critical needs in the healthcare sector, specifically within the interventional cardiology and electrophysiology markets. Its market position is defined by a commitment to expanding access to high-quality care through technological advancement and operational efficiency.
How much funding has Stereotaxis raised?
Stereotaxis has raised a total of $497.1M across 23 funding rounds:
Stock Offering
$10.2M
Debt
$10M
Share Placement
$24M
Other Financing Round
$10M
Share Placement
$25M
Debt
$2M
Share Placement
$15M
Other Financing Round
$50M
Stock Issuance/Offering (2013): $10.2M with participation from Undisclosed
Debt (2014): $10M led by Silicon Valley Bank
Share Placement (2016): $24M supported by Joe Kiani and DAFNA Capital Management
Other Financing Round (2018): $10M featuring Undisclosed
Share Placement (2019): $25M backed by Parkman Healthcare Partners, Redmile Group, and Opaleye Management
Debt (2020): $2M with participation from PPP
Share Placement (2020): $15M led by Consonance Capital Management
Other Financing Round (2025): $50M supported by Roth Capital Partners
Key Investors in Stereotaxis
Advent International
Advent International is a leading global private equity firm specializing in buyouts, growth equity, and strategic restructuring across the healthcare and technology sectors.
Ascension Ventures
Ascension Ventures is a strategic healthcare venture firm that invests on behalf of leading community health systems to support companies transforming the healthcare industry.
Johnson & Johnson Development Corporation
Johnson & Johnson Development Corporation is the venture capital arm of the global healthcare giant, focusing on innovative medical technologies and pharmaceutical advancements.
What's next for Stereotaxis?
With the successful completion of this recent strategic investment, Stereotaxis is well-positioned to advance its next phase of commercial expansion and product development. The company is expected to prioritize the integration of its robotic platforms into a broader range of clinical settings, focusing on enhancing the intelligence and connectivity of its existing ecosystem. As the firm navigates the evolving landscape of medical technology, this capital will likely support the refinement of its surgical instruments and the expansion of its global footprint, ensuring that its robotic solutions remain at the forefront of endovascular care.
See full Stereotaxis company page
